If they are paying 10% it is because there are no shares available, 10% is a nice carrot to get longs to work against their own position. I wonder what rate they are charging the shorts, if they are paying 10%to longs. I for one think all longs should pull their shares from the short pool, if that happened the stock would move a tad more than 10%. As is, AIG isn't getting many longs to work against their position lately, 1k shares available this AM.
Getting the CPT code will benefit both patients and doctors. It will reduce the number of biopsies that patients have to endure, plus it benefits the doctors by lowering medical insurance. Biopsies cause many complications, patients who end up with issues turn around and sue the doctors. This will ultimately be an in office test the Dr. can charge for, so it will generate an income, and also reduce medical liability.
Biopsies miss cancers, and a Dr. can get sued when it later turns out the patient indeed had cancer, not a good situation. 4k, misses no more than a biopsy would, but an elevated 4k score puts the patient on watch for a follow up test, which is fast, easy, and noninvasive. Far better choice than a second biopsy.
This test will ramp up slow but will gain traction, the cpt code will be a catalyst.
“Regarding 4Kscore, the AMA will hold its CPT editorial panel meeting on 10/9-10/11 where it will render a decision on a CPT code. Management continues to anticipate CPT issuance in 1Q15.”
only 40k, on Friday, which was down from 1.9m, two weeks ago. Current availability spiked to 2k, oops, drying up. Ammo getting scarce.
Ron sees advancements in phase studies, presentations at asco etc., as milestone events, the market yawns. The events that might impact share price are way beyond the control of Ron, or anyone at Array. The phase 3 studies at Novartis and Astra if good are 6 and 9 months off and the only true catalysts.
Ron cannot speed that up, it is out of his hands. In fact Novartis could give mek 162 back, Astra could get their mek to the Nda stage, and arry might not rise above 4.00. The share price is up to the market, not the Ceo. Ron when asked about catalysts is obligated to lay out the time line for the pipeline, the market is not rewarding those at all.
The best scenario is two NDA's, but then there will still be no revenue, and the ATM will still be diluting our position. The real catalyst here is REVENUE, and that needs the other catalysts to pan out, and revenue will not happen until 2016. So, flip it for dimes and quarters to make the wait less painful, but this will take MORE time, 6-9 months minimum, 18 months max, with the gamble that phase studies pan out.
The company will start three new phase studies, and do the NDA in the next 12 weeks, 6 revenue generators hitting the market over the next year. This will get to the Oppenheimer current price target before then, and he will raise it to 16-18 before eoy/2015.
Wonder if it is the Iphone app driving visits to check 4k results by Drs. Not out of the realm of possibility.
Talk about short memory. His calls are always right???
in an over crowded position.
Short bagholders know, first to cover wins, last to cover the biggest bagholder. Greedy greedy.
Cpt for 4k due before March. Now, noway to know about Rayaldee, BUT it will be fast. I say that based on last CC, they stated they are already in talks with insurers about that drug even though the nda has not been filed. Keep in mind these renal guys are the best. They built up a top tier renal company after they invented Hectoral, the top selling ckd D hormone. They are convinced they have built a way better mouse trap, they are working behind the scenes to hit the ground running. I think that gets insurance coverage in under 90 days once approved, they are in contact with private insurers NOW.
Rolapitant by Aug, we can market in South America, Rayaldee by appx Oct, so late 2015, PSA, testosterone, by July, Vitamin D test by Oct. Usually a 10 month time frame after NDA is accepted, total time 1 year, So Oct is pushing it. This drug will be way bigger than many think.
I know every one looks to Frost, but I am really impressed with the Cytochroma team. Those guys are some of the best on the planet when it comes to vitamin D, ckd, and getting drugs approved. They invented some of the current market leading products, and now they figure their new drug Rayaldee will take that position.
Thank tipranks, lol, I just relayed their info, the messenger, lol. I have trouble buying the idea of 100% success rate, but I guess it is possible.
Rohit Vanjani has a total average return of 42.9% and a 100.0% success rate according to tipranks who evaluates analysts, Vanjani is ranked in the upper 1/3 of all analysts according to tipranks.
Just put those types on ignore. Frost has given more money back to society, to the education system, to the arts, than anyone in the state of Florida. He plans on donating over another billion as a pledge. These guys that rant here, what have they done in life, or to make their parents proud or given back to society, Nothing? I can say that because those who have achieved true wealth wish harm to no one and wish everyone do well, and stay in good health. Those with wealth usually are NOT bitter or envious of others success, but thankful for their own. So consider the source, pity them if you must, then use the ignore button. It is the only MORAL thing to do.
The psa and testosterone will finish up quickly, 5-6 months, Type 2 diabetes will take longer and depend on design.
If you copy opko health's ceo etc... into browser it brings up the seeking alpha transcript.